Outcomes for systemic therapy in older patients with metastatic melanoma: Results from the Dutch Melanoma Treatment Registry
Authors:
Open Access
- 1 September 2021
- journal article
- research article
- Published by Elsevier in Journal of Geriatric Oncology
- Vol. 12 (7) , 1031-1038
Abstract
No abstract availableKeywords
Funding Information
- Novartis
- Meso Scale Diagnostics
- Bristol-Myers Squibb
- ZonMw (836002002)
- GlaxoSmithKline
This publication has 31 references indexed in Scilit:
- Nivolumab in Previously Untreated Melanoma withoutBRAFMutationNew England Journal of Medicine, 2015
- Combined Vemurafenib and Cobimetinib in BRAF-Mutated MelanomaNew England Journal of Medicine, 2014
- International Society of Geriatric Oncology Consensus on Geriatric Assessment in Older Patients With CancerJournal of Clinical Oncology, 2014
- Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programmeJournal of Experimental & Clinical Cancer Research, 2014
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trialThe Lancet, 2012
- Predicting Chemotherapy Toxicity in Older Adults With Cancer: A Prospective Multicenter StudyJournal of Clinical Oncology, 2011
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic MelanomaNew England Journal of Medicine, 2011
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor sitePigment Cell & Melanoma Research, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010